EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced the European Commission (EC) has granted orphan drug status for sirolimus (DE-109) for the treatment of chronic non-infectious uveitis. The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) in June. Orphan designation will be published on the EMA website.
